Objective: To systematically evaluate the efficacy and safety of Yangxue Qingnao granule (YQG) in treating vascular dementia (VD). Method: A computerized literature retrieval was carried out in main Chinese and English databases to collect randomized controlled trials (RCTs) for YQG in treating VD. The quality of all included trials was evaluated according to the Cochrane Handbook 5.1.RevMan 5.3 software was applied in a Meta-analysis on included studies. Funnel plot and Egger's test were used to analyze the publication bias. The quality of evidences was evaluated by GRADE profiler 3.6.1 software. Result: Altogether 10 studies were included. According to the Meta-analysis

compared with the conventional treatment with western medicines

the treatment with YQG showed statistical difference in mini-mental state examination (MMSE) scores [WMD=2.12

95%CI (1.61

2.63)]

Hasegawa dementia scale(HDS) scores [WMD=3.98

95%CI (3.16

4.79)] and activity of daily living (ADL) scores [SMD=-0.62

95%CI (-0.80

-0.44)]. On the basis of the subgroup analysis on MMSE score

the treatment measures based on the YQG group was superior to that of the donepezil group

the nimodipine group and the piracetam group

with higher safety evaluation and no publication bias. The GRADE profile showed a low quality of evidences. Conclusion: The treatment measures based on YQG was superior to that of the conventional western medicines. However

clinicians shall sue the evidence cautiously due to the low methodology quality

a small number of studies included and lower evidence grade.